Premium
Development of the technology for ‘Diprifusor’ TCI systems[Note 1. ‘Diprifusor’ and ‘Diprivan’ are trademarks, the property of Zeneca ...]
Author(s) -
Gray J. M.,
Kenny G. N. C.
Publication year - 1998
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1111/j.1365-2044.1998.53s114.x
Subject(s) - medicine , pharmacokinetics , infusion pump , anesthesia , target controlled infusion , syringe driver , pharmacodynamics , component (thermodynamics) , syringe , intensive care medicine , propofol , pharmacology , remifentanil , psychiatry , physics , thermodynamics
The availability of fast‐acting intravenous drugs for anaesthesia has encouraged anaesthetists to gain a practical understanding of the pharmacodynamics and pharmacokinetics of these drugs to optimise their administration. ‘Diprifusor’ technology uses pharmacokinetic modelling to control the infusion rate of a pump, providing the anaesthetist with direct control of the blood concentration rather than indirect control by the infusion rate. The ‘Diprifusor’ electronics module is a dual microprocessor component that can be incorporated into an infusion pump to provide this mode of administration. This paper describes the module's infusion control system, prefilled syringe recognition system and the safety aspects addressed by the design.